Clinical trials: Hematologic Malignancy, open to volunteers
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study…
- Trial name
- NCT07785180
- Testing
- Chemotherapy
- Where
- 67 sites in Denmark, France and 9 more
- Volunteers
- 140 people
- Sponsor
- Stemline Therapeutics, Inc.
Multiple Myeloma, Smoldering Multiple Myeloma
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk…
- Trial name
- iStopMM (NCT03815279)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- Iceland
- Volunteers
- 80 people
- Sponsor
- Landspitali University Hospital
Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma, Hairy Cell Leukemia (HCL)
- Trial name
- IMPACT (NCT07759661)
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- IRCCS San Raffaele
Relapsed Acute Myeloid Leukemia
Imetelstat Combinations in Relapsed AML
IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML.
- Trial name
- IMAGINE (NCT07320235)
- Testing
- Imetelstat, Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Douglas Tremblay
Myelodysplastic Syndromes, High Risk
Sonrotoclax Plus Azacitidine in Patients With MDS-IB2
This study will evaluate the safety and preliminary effectiveness of sonrotoclax combined with azacitidine in adults aged 18-70 years with newly diagnosed myelodysplastic neoplasms with increased blasts-2 (MDS-IB2).
- Trial name
- NCT07885397
- Testing
- Sonrotoclax, Azacitidine (AZA)
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Adult
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
- Trial name
- NCT05133882
- Testing
- Clifutinib Besylate
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Cancer, Chronic Lymphocytic Leukemia
Time Restricted Eating in Haematological Malignancies
The goal of this clinical trial is to learn if time restricted eating (TRE), a form of intermittent fasting, can impact health outcomes in patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06862323
- Testing
- Time-Restricted Eating
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
AML, Adult
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
Mutations in IDH genes are found in numerous cancers and more specifically in acute myeloid leukemia (AML). These mutations target specific amino acids, at positions 140 or 172 of IDH2, and 132 of IDH1.
- Trial name
- NCT06377579
- Where
- 21 sites in France
- Volunteers
- 250 people
- Sponsor
- French Innovative Leukemia Organisation
Multiple Myeloma or Plasmacytoma
Engineered Dendritic Cell Vaccines for Multiple Myeloma
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac).
- Trial name
- NCT06435910
- Testing
- DC vaccines
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Multiple Myeloma, Fall Risk Factors
Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
Approximately one third of the population over the age of 65 falls at least once a year. The risk of falling is in increased in older patients with tumor diseases.
- Conditions
- Multiple Myeloma, Fall Risk Factors, Strength Training Effects, Balance Training Effects
- Trial name
- Myfall (NCT07044427)
- Testing
- Strength and balance training in combination with a treadmill-based pertubation intervention
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Heidelberg
Thrombocytopenia
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
The purpose of this study is to study how avatrombopag (the study drug) may prevent certain side effects in adults with lymphoma and myeloma getting cancer treatment (CAR-T cell therapy).
- Trial name
- CAR-T 002 (NCT07895017)
- Testing
- Avatrombopag
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Virginia
Hematologic Malignancy
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
This study investigates how metabolism in cancer and immune cells shapes the bone marrow environment, influences therapy resistance, and affects outcomes in hematological malignancies.
- Trial name
- NCT07189117
- Where
- Switzerland
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hematopoietic and Lymphoid Cell Neoplasm
Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors
This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell…
- Trial name
- NCT04892823
- Testing
- Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia, Graft Versus Host Disease
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute…
- Conditions
- Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
- Trial name
- NCT06996119
- Testing
- Biospecimen Collection, Busulfan, Computed Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Acute Lymphoblastic Leukemia ALL
Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
The goal of this study is to explore the trajectory patterns of chemotherapy induced peripheral neuropathy over the course of chemotherapy and identify predictors of distinct trajectories in children with acute lymphoblastic…
- Trial name
- NCT07326930
- Where
- 3 sites in China
- Volunteers
- 173 people
- Sponsor
- The Hong Kong Polytechnic University
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT07582159
- Testing
- Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Chronic Lymphocytic Leukemia
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in western countries. CLL is most often discovered incidentally when a blood test carried out for another reason highlights an increase of subpopulation of…
- Trial name
- NCT06475469
- Testing
- Blood sampling & Chest CT without injection
- Where
- France
- Volunteers
- 75 people
- Sponsor
- CHU de Reims
Acute Myeloid Leukemia
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
This study evaluates the efficacy and safety of the combination of idarubicin and cytarabine induction followed by intermediate-dose cytarabine consolidation with venetoclax in the treatment of newly diagnosed adult acute myeloid…
- Trial name
- NCT06232694
- Testing
- Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;, Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;, utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hematological Malignancy
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate .
- Trial name
- NCT03850366
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL)
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
- Conditions
- Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
- Trial name
- COURAGE (NCT06914037)
- Testing
- CHT101
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.